A shift in the balance between two lipids – cholesterol and sphingomyelin – makes hybrid epithelial-mesenchymal cancer cells less responsive to certain chemotherapy drugs.

Lipid imbalance triggered by Snail-driven epithelial–mesenchymal transition creates a cholesterol-dependent vulnerability ...

ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, today announced that it has entered into a collaboration agreement with Fosun Kairos ...

NeuroScientific Biopharmaceuticals’ stem cell tech has delivered real-world promise for those with Crohn’s disease, ...

On November 2, 2025, the research group led by Dr. Zeng Ling from Army Medical University systematically elucidated the molecular mechanisms, ...

We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and ...

Under the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche of RMB 1 million and a second tranche of RMB 5 million, subject to the ...

Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

A Swedish startup aims to dominate stem cell production while nanotechnology is helping to transform cancer care. What does ...

Scientists uncovered how the protein Piezo1 translates physical activity into stronger bones, offering a path to ...

Mesoblast (MESO) stock jumps as the company's lead asset Ryoncil adds $35.1M in revenue during the December quarter, marking ...